exanthema

Summary

Summary: Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.

Top Publications

  1. ncbi [Drug rash with eosinophilia and systemic symptoms (DRESS) attributed to the oral skin-care supplement Imedeen]
    J F van Leeuwen
    Inspectie voor de Gezondheidszorg, Postbus 16 119, 2500 BC Den Haag
    Ned Tijdschr Geneeskd 149:1353-6. 2005
  2. pmc Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
    Mario E Lacouture
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion Suite 228, 160 East 53rd Street, New York, NY 10022, USA
    Support Care Cancer 19:1079-95. 2011
  3. ncbi Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib
    Yelena Y Janjigian
    Gastrointestinal and Thoracic Oncology Services, Division of Solid Tumor Oncology, Department of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10065, USA
    Clin Cancer Res 17:2521-7. 2011
  4. ncbi Skin toxicities associated with epidermal growth factor receptor inhibitors
    Tianhong Li
    Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Target Oncol 4:107-19. 2009
  5. ncbi Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center Albert Einstein College of Medicine, 111 E 210th St, Bronx, NY 10467, USA
    J Clin Oncol 22:3238-47. 2004
  6. pmc Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)
    Aminah Jatoi
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 113:847-53. 2008
  7. ncbi Zika virus outbreak on Yap Island, Federated States of Micronesia
    Mark R Duffy
    Division of Vector Borne Infectious Diseases, National Center for Zoonotic, Vector Borne, and Enteric Diseases, Centers for Disease Control and Prevention, Fort Collins, CO 80521, USA
    N Engl J Med 360:2536-43. 2009
  8. ncbi Systemic drug-related intertriginous and flexural exanthema (SDRIFE)
    Sarina B Elmariah
    Department of Dermatology, New York University, USA
    Dermatol Online J 15:3. 2009
  9. ncbi Papular purpuric rash due to parvovirus B19 with distribution on the distal extremities and the face
    Liora Harel
    Department of Pediatrics C, Schneider Children s Medical Center of Israel, Petah Tikva, 49202 Israel
    Clin Infect Dis 35:1558-61. 2002
  10. ncbi Symmetrical drug-related intertriginous and flexural exanthema
    Sze Chin Tan
    Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore
    Curr Opin Allergy Clin Immunol 11:313-8. 2011

Research Grants

  1. EIGHTEENTH INTERNATIONAL HERPES VIRUS MEETING
    Joseph Glorioso; Fiscal Year: 1993
  2. ANALYSIS OF THE HUMAN HERPESVIRUS 6 GENOMIC TERMINI
    GARY LINDQUESTER; Fiscal Year: 1992
  3. PATHOPHYSIOLOGY OF VARICELLA ZOSTER VIRUS INFECTION
    Martin Myers; Fiscal Year: 1980
  4. GLYCOPROTEINS OF HUMAN HERPESVIRUS-6
    Bala Chandran; Fiscal Year: 1992
  5. Varicella Zoster Virus:Clinical Implications of Immunity
    Saul Silverstein; Fiscal Year: 2003
  6. DNA SCREENING ASSAY FOR HUMAN HERPES VIRUS
    Frank White; Fiscal Year: 1993
  7. Mechanisms and Therapeutics in Cancer Anorexia/Cachexia
    Aminah Jatoi; Fiscal Year: 2004
  8. Creatine: Is It a Body Builder for Cancer Patients?
    Aminah Jatoi; Fiscal Year: 2004
  9. Neuropeptide Y for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2003
  10. Chemotherapy and anti-EGFR Antibody C225 in Lung Cancer
    Roman Perez Soler; Fiscal Year: 2004

Detail Information

Publications254 found, 100 shown here

  1. ncbi [Drug rash with eosinophilia and systemic symptoms (DRESS) attributed to the oral skin-care supplement Imedeen]
    J F van Leeuwen
    Inspectie voor de Gezondheidszorg, Postbus 16 119, 2500 BC Den Haag
    Ned Tijdschr Geneeskd 149:1353-6. 2005
    ..Single or multiple organ involvement, especially of the liver, kidney, lungs and/or heart, is also common. The syndrome is associated with a number of different drugs...
  2. pmc Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
    Mario E Lacouture
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion Suite 228, 160 East 53rd Street, New York, NY 10022, USA
    Support Care Cancer 19:1079-95. 2011
    ..The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities...
  3. ncbi Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib
    Yelena Y Janjigian
    Gastrointestinal and Thoracic Oncology Services, Division of Solid Tumor Oncology, Department of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10065, USA
    Clin Cancer Res 17:2521-7. 2011
    ..To evaluate the toxicity and efficacy of cetuximab and erlotinib in patients with acquired resistance to erlotinib, we conducted this phase I/II clinical trial...
  4. ncbi Skin toxicities associated with epidermal growth factor receptor inhibitors
    Tianhong Li
    Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Target Oncol 4:107-19. 2009
    ..A randomized, double-blinded, placebo-controlled study has been initiated to evaluate the clinical efficacy of menadione topical cream, in the treatment or prevention of EGFR inhibitor-induced skin toxicity...
  5. ncbi Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center Albert Einstein College of Medicine, 111 E 210th St, Bronx, NY 10467, USA
    J Clin Oncol 22:3238-47. 2004
    ..This phase II study of erlotinib in patients with HER1/EGFR-expressing non-small-cell lung cancer previously treated with platinum-based chemotherapy evaluated tumor response, survival, and symptom improvement...
  6. pmc Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)
    Aminah Jatoi
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 113:847-53. 2008
    ..Epidermal growth factor receptor (EGFR) inhibitors are effective cancer therapies, but they are reported to cause a rash in >50% of patients. In the current study, the authors examined the use of tetracycline for rash prevention...
  7. ncbi Zika virus outbreak on Yap Island, Federated States of Micronesia
    Mark R Duffy
    Division of Vector Borne Infectious Diseases, National Center for Zoonotic, Vector Borne, and Enteric Diseases, Centers for Disease Control and Prevention, Fort Collins, CO 80521, USA
    N Engl J Med 360:2536-43. 2009
    ..No previous outbreaks and only 14 cases of Zika virus disease have been previously documented...
  8. ncbi Systemic drug-related intertriginous and flexural exanthema (SDRIFE)
    Sarina B Elmariah
    Department of Dermatology, New York University, USA
    Dermatol Online J 15:3. 2009
    ..The clinical and histopathologic findings were consistent with systemic drug-related intertriginous and flexural exanthema (SDRIFE), which is an uncommon drug reaction that results in symmetric erythema that affects the buttocks, groin,..
  9. ncbi Papular purpuric rash due to parvovirus B19 with distribution on the distal extremities and the face
    Liora Harel
    Department of Pediatrics C, Schneider Children s Medical Center of Israel, Petah Tikva, 49202 Israel
    Clin Infect Dis 35:1558-61. 2002
    ..Serologic analysis for parvovirus B19 yielded positive results. Parvovirus B19 should be included in the evaluation of febrile purpura...
  10. ncbi Symmetrical drug-related intertriginous and flexural exanthema
    Sze Chin Tan
    Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore
    Curr Opin Allergy Clin Immunol 11:313-8. 2011
    Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), previously termed drug-related baboon syndrome, is a benign and self-limiting type IV hypersensitivity reaction characterized by symmetrical erythema involving the ..
  11. ncbi Generalized petechial rashes in children during a parvovirus B19 outbreak
    M Bruce Edmonson
    Division of General Pediatrics and Adolescent Medicine, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    Pediatrics 125:e787-92. 2010
    ....
  12. ncbi Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center, Bronx, NY, USA
    J Clin Oncol 23:5235-46. 2005
    ..The cause of the possible relationship between rash and clinical benefit remains unclear at this time, and additional studies are needed to determine the clinical utility of this observation...
  13. ncbi First case of symmetric drug-related intertriginous and flexural exanthema (sdrife) due to rivastigmine?
    Gwenaëlle Allain-Veyrac
    Clinical Pharmacology Department, CHU de Nantes, France
    Am J Clin Dermatol 12:210-3. 2011
    ..2004, some authors proposed the acronym SDRIFE standing for 'symmetric drug-related intertriginous and flexural exanthema' specifically for cases elicited by systemically administered drugs...
  14. ncbi A study of the specificity of lymphocytes in nevirapine-induced skin rash
    Xin Chen
    Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Canada M5S 3M2
    J Pharmacol Exp Ther 331:836-41. 2009
    ..This has significant implications for understanding the evolution of an immune response and the basis of the pharmacological interaction hypothesis...
  15. ncbi Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center, Division of Medical Oncology, Albert Einstein College of Medicine, New York, New York, USA
    Oncology (Williston Park) 17:23-8. 2003
    ..Further study of the potentially important association between rash and outcome of treatment with EGFR-targeted agents is needed...
  16. ncbi Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Oncologist 13:1201-4. 2008
    ..It suggests that quality of life issues should remain at the forefront as cancer patients and health care providers make decisions about holding cancer therapy...
  17. ncbi Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update
    S Tas
    Department of Dermatology, Erasme University Hospital, Brussels, Belgium
    Dermatology 206:353-6. 2003
    ..In the absence of a well-established therapy, primary and secondary prevention have a key role in the management of DRESS syndrome...
  18. pmc Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib
    Bruno Vincenzi
    Department of Surgical and Oncological Sciences, Section of Medical Oncology Università di Palermo, Palermo, Italy, Via del Vespro 127, 90127 Palermo, Italy
    Oncologist 15:85-92. 2010
    ..This study was conducted to assess the link between the antitumor efficacy of sorafenib and its early cutaneous side effects in advanced HCC patients...
  19. ncbi Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda
    Fatu Forna
    Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Acquir Immune Defic Syndr 44:456-62. 2007
    ..We evaluated clinical toxicity in HIV-infected persons receiving antiretroviral therapy (ART) in Uganda...
  20. ncbi Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
    Denis Soulieres
    CHUM, Hospital Notre Dame, Montreal, Quebec, Canada
    J Clin Oncol 22:77-85. 2004
    ..To determine the efficacy and safety profiles of erlotinib in patients with advanced recurrent and/or metastatic squamous cell cancer of the head and neck (HNSCC)...
  21. ncbi Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer
    Paolo Bidoli
    Medical Oncology Unit, S Gerardo Hospital, Monza, Italy
    J Thorac Oncol 5:1662-3. 2010
    ..No effective treatment for the rash is available...
  22. ncbi Up-regulation of CCL17, CCL22 and CCR4 in drug-induced maculopapular exanthema
    B Tapia
    Research Unit, Hospital Universitario La Paz, Madrid, Spain
    Clin Exp Allergy 37:704-13. 2007
    Maculopapular exanthema has been reported to be the most frequently drug-induced cutaneous reaction...
  23. ncbi Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies
    Bret Wacker
    OSI Pharmaceuticals, Boulder, Colorado 80301, USA
    Clin Cancer Res 13:3913-21. 2007
    ..Data from two large phase III studies were analyzed to characterize the correlation between the occurrence of rash during treatment with the epidermal growth factor receptor inhibitor erlotinib and improved clinical outcomes...
  24. ncbi Tula virus infection associated with fever and exanthema after a wild rodent bite
    D Schultze
    Department of Virology, Institute for Clinical Microbiology and Immunology, Frohbergstrasse 3, 9001 St Gallen, Switzerland
    Eur J Clin Microbiol Infect Dis 21:304-6. 2002
    ..In this case, paronychia, fever and exanthema occurred after the patient was bitten by a wild rodent, indicating an unusual route of hantavirus transmission...
  25. ncbi Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Heinz Josef Lenz
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    J Clin Oncol 24:4914-21. 2006
    ..It also evaluated the safety, pharmacokinetics, immunokinetics, and biologic determinants of activity...
  26. ncbi Cytokine and chemokine expression in the skin from patients with maculopapular exanthema to drugs
    T D Fernandez
    Research Laboratory for Allergic Diseases, Carlos Haya Hospital Fundacion IMABIS, Malaga, Spain
    Allergy 63:712-9. 2008
    Maculopapular exanthema (MPE) is the most frequent clinical manifestation of nonimmediate allergic reactions to drugs and T helper 1 (Th1) cytokines and CD4(+) T cells have been shown to play an important role in its pathogenesis...
  27. ncbi Carbamazepine-induced DRESS syndrome with recurrent fever and exanthema
    Julia Valencak
    Department of Dermatology, Division of General Dermatology, University of Vienna, Vienna, Austria
    Int J Dermatol 43:51-4. 2004
  28. ncbi Managing cutaneous reactions to imatinib therapy
    Simon A J Rule
    Blood 100:3434-5. 2002
  29. ncbi Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature
    Miguel A Park
    Division of Allergic Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Allergy Asthma Proc 25:345-7. 2004
    ..We describe a case of a successful progressive challenge of a patient with a drug-induced exanthem from imatinib mesylate and a review of the literature...
  30. ncbi Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients
    Laurence Valeyrie
    Department of Dermatology, Henri Mondor Hospital Assistance Publique Hôpitaux de Paris, Paris XII University, F 94010 Paris Cedex, France
    J Am Acad Dermatol 48:201-6. 2003
    ..Imatinib is a new major treatment in chronic myeloid leukemia...
  31. ncbi The Schnitzler syndrome. Four new cases and review of the literature
    D Lipsker
    Clinique Dermatologique, Hopitaux Universitaires, Strasbourg, France
    Medicine (Baltimore) 80:37-44. 2001
    ..In some patients, these symptoms and/or the presence of severe inflammatory anemia require steroids and/or immunosuppressive treatment, which ameliorate inflammatory symptoms but do not change the course of the skin rash...
  32. ncbi Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    David Cunningham
    Royal Marsden Hospital, London, United Kingdom
    N Engl J Med 351:337-45. 2004
    ..We compared the efficacy of cetuximab in combination with irinotecan with that of cetuximab alone in metastatic colorectal cancer that was refractory to treatment with irinotecan...
  33. ncbi Dermatomyositis
    Jeffrey P Callen
    Division of Dermatology, University of Louisville School of Medicine, KY 40202, USA
    Clin Dermatol 24:363-73. 2006
    ..Therapy of the skin disease begins with photoprotection and topical corticosteroids, but also includes the use of antimalarial agents and immunomodulatory therapies...
  34. ncbi Pathogenesis of drug-induced exanthems
    W Pichler
    Division of Allergology, Clinic for Rheumatology and Clinical Immunology Allergology, Inselspital, University of Bern, Switzerland
    Allergy 57:884-93. 2002
  35. ncbi Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management
    Sotirios Tsimboukis
    Oncology Unit, Third Department of Medicine, Athens Medical School, Sotiria General Hospital, Greece
    Clin Lung Cancer 10:106-11. 2009
    ....
  36. ncbi Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria
    A Maiolino
    University Hospital, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
    Bone Marrow Transplant 31:393-7. 2003
    ..0007). The prospective application of these diagnostic criteria may have a favorable impact on the early diagnosis of the syndrome, with the initiation of corticosteroids and a reduction in the unnecessary use of antimicrobial agents...
  37. doi The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects
    Peter Arne Gerber
    J Clin Oncol 26:2790-2. 2008
  38. ncbi Cross-sensitivity between paroxetine and sertraline
    Caroline A Warnock
    Department of Pharmaceutical Services, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Ann Pharmacother 36:631-3. 2002
    ..To report a case of possible cross-sensitivity between selective serotonin-reuptake inhibitors (SSRIs)...
  39. ncbi Simian varicella virus infects ganglia before rash in experimentally infected monkeys
    R Mahalingam
    Department of Neurology, University of Colorado Health Sciences Center, Denver, Colorado, 80262, USA
    Virology 279:339-42. 2001
    ..Like other organs, monkey ganglia become infected with SVV before the appearance of rash...
  40. pmc Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4)
    Aminah Jatoi
    Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    Oncologist 15:1016-22. 2010
    ..Rash occurs in >50% of patients prescribed epidermal growth factor receptor (EGFR) inhibitors. This study was undertaken to determine whether sunscreen prevents or mitigates these rashes...
  41. ncbi Sparing of previously irradiated skin from erlotinib-induced acneiform rash
    Suayib Yalcin
    J Am Acad Dermatol 58:178-9. 2008
  42. ncbi Acute exanthematous pustular drug eruption induced by mexiletine
    K Sasaki
    Department of Dermatology, Tokyo Medical and Dental University, School of Medicine, 1 5 45 Yushima, Bunkyo ku, Tokyo 113 8519, Japan
    Eur J Dermatol 11:469-71. 2001
    ..We conclude that pustules, infiltrated erythema and facial edema were the signs of acute exanthematous pustular drug eruption induced by mexiletine hydrochloride...
  43. ncbi Aminopenicillin-induced exanthema allows treatment with certain cephalosporins or phenoxymethyl penicillin
    Jiri Trcka
    Department of Dermatology, Venerology and Allergology, University of Wurzburg, Wurzburg, Germany
    J Antimicrob Chemother 60:107-11. 2007
    Aminopenicillin-induced exanthema poses a problem in the management of infectious diseases. Due to theoretically possible immunological cross-reactivity, all beta-lactam drugs, i.e...
  44. ncbi Temporal dependence of the effect of radiation on erlotinib-induced skin rash
    Mario E Lacouture
    J Clin Oncol 25:2140; author reply 2141. 2007
  45. ncbi Practical management of patients with non-small-cell lung cancer treated with gefitinib
    Neelam T Shah
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 23:165-74. 2005
    ..Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer...
  46. pmc A 33-year-old man with a facial rash
    John Fleming
    Imperial College, London, United Kingdom
    PLoS Med 1:e17; quiz e12. 2004
  47. ncbi Streptococcal toxic shock syndrome with initial manifestation of abdominal pain and cholecystitis
    Te Yu Hung
    Chi Mei Foundation Medical Center, Department of Pediatrics, Yung Kang City, Taiwan
    Acta Paediatr Taiwan 46:106-10. 2005
    ..These clinical findings and the plasma analysis were consistent with streptococcal toxic shock syndrome...
  48. ncbi Acute respiratory distress syndrome in a child with Kawasaki disease
    April Lynne Palmer
    University of Mississippi Medical Center, Department of Pediatrics, Jackson, MS 39216 4505, USA
    South Med J 98:1031-3. 2005
    ..The severity of the patient's pulmonary disease led clinicians to suspect toxic shock syndrome. Clinicians need to be aware that pulmonary manifestations of Kawasaki disease can include acute respiratory distress syndrome...
  49. ncbi Rash and fever in an ill-appearing child
    Carol L Blackwood
    Naval Hospital Jacksonville, FL 32244, USA
    Am Fam Physician 70:361-3. 2004
  50. ncbi [Laboratory diagnosis of patients with exanthematic or febrile syndromes occurring in the Zulia State, Venezuela, during 1998]
    Luciana Costa de Leóna
    Escuela de Bioanalisis, Facultad de Medicina, Instituto de Investigaciones Clinicas, Universidad del Zulia, Maracaibo, Venezuela
    Rev Med Chil 132:1078-84. 2004
    ..Exanthematic diseases are a group of syndromes mainly caused by acute viral infections...
  51. ncbi Ciprofloxacin-induced acute generalized exanthematous pustulosis mimicking bullous drug eruption confirmed by a positive patch test
    P Hausermann
    Department of Dermatology, University Hospital Basel, Switzerland
    Dermatology 211:277-80. 2005
    ..Furthermore, we highlight in this particular case the challenging differentiation from bullous drug eruption...
  52. ncbi Histopathology of drug-induced exanthems: is there a role in diagnosis of drug allergy?
    Marcel Brönnimann
    Department of Dermatology, University Hospital, Bern, Switzerland
    Curr Opin Allergy Clin Immunol 5:317-21. 2005
    ..This review focuses on histopathological and immunohistochemical findings of drug-induced maculo-papular exanthems and discusses the value of skin biopsies and consequent histopathological examination in the diagnosis of these reactions...
  53. ncbi Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome
    M Gonzalez-Vicent
    Department of Pediatric Hematology and Oncology, Hospital Nino Jesus, Universidad Autonoma, Madrid, Spain
    Bone Marrow Transplant 34:1051-5. 2004
    ..A high number of CD34+ cells/kg infused, patients transplanted in early phase, the type of malignancy (solid tumor) and conditioning regimens other than busulfan based were significantly associated with ES in a multivariate analysis...
  54. ncbi Drug rash with eosinophilia and systemic symptoms induced by lamotrigine therapy
    N Parri
    Int J Immunopathol Pharmacol 20:643-5. 2007
  55. ncbi [Cutaneous drug reactions]
    Claus Lützow-Holm
    Hudavdelingen, Ulleval universitetssykehus, 0407 Oslo
    Tidsskr Nor Laegeforen 125:2483-7. 2005
    ..Adverse cutaneous reactions to drugs are frequent in general practice. This article is a review of current knowledge of the pathogenesis, differential diagnosis and practical management of this wide spectrum of cutaneous manifestations...
  56. ncbi Macrophage activation syndrome
    M K Kumar
    Department of Internal Medicine, Medical College Hospital, Trivandrum
    J Assoc Physicians India 54:238-40. 2006
    ..We report a case in which a female admitted with fever and rash, initially had systemic inflammatory response syndrome (SIRS) like clinical presentation, but eventually proved to be a rare case of fatal Macrophage Activation Syndrome...
  57. ncbi Case records of the Massachusetts General Hospital. Case 36-2007. A 31-year-old woman with rash, fever, and hypotension
    Marc S Sabatine
    Cardiovascular Division, Brigham and Women s Hospital, Boston, USA
    N Engl J Med 357:2167-78. 2007
  58. ncbi Allergic contact dermatitis from a topical corticosteroid mimicking acute generalized exanthematous pustulosis
    Sigurd Broesby-Olsen
    Acta Derm Venereol 85:444-5. 2005
  59. ncbi Possible drug rash with eosinophilia and systemic symptoms syndrome after exposure to epoetin alfa
    Nick Norgard
    Iowa Methodist Medical Center IMMC, Des Moines, IA, USA
    Am J Health Syst Pharm 62:2524-6. 2005
  60. ncbi [Adverse effects and safety of antimicrobial agents--allergy]
    Zenro Ikezawa
    Department of Dermatology, Yokohama City University Graduate School of Medicine
    Nihon Rinsho 65:578-86. 2007
  61. ncbi Murine typhus in Cyprus: 21 paediatric cases
    M Koliou
    Department of Paediatrics, Infectious Diseases and Immunology Unit, Archbishop Makarios Hospital, Nicosia, Cyprus
    Eur J Clin Microbiol Infect Dis 26:491-3. 2007
    ..Rickettsia typhi infection should be considered in the differential diagnosis of children who present during the summer or early autumn months with prolonged fever and rash with or without lymphadenopathy...
  62. ncbi Adult onset Still's disease: a study of 14 cases
    S Singh
    Department of Rheumatology, P D Hinduja National Hospital and Medical Research Center, V S Marg, Mahim w, Mumbai 16, India
    Clin Rheumatol 27:35-9. 2008
    ..Nonsteroidal anti-inflammatory drugs, steroids, and methotrexate may not be always effective, and cyclosporine is an effective drug in resistant cases. Sulfasalazine should be avoided in cases of AOSD...
  63. ncbi [Fever and maculopapular exanthema as first manifestation of lymphoma]
    F J Fernández Fernández
    An Med Interna 24:204-5. 2007
  64. ncbi [Brown recluse bite]
    Moshe Nehemya
    Kaplan Medical Center, Rehovot
    Harefuah 147:672-6, 752. 2008
    ..The objective of this review is to increase awareness towards recluse bites, thereby preventing misdiagnoses and unnecessary treatments...
  65. ncbi [Clinical analysis of childhood acute generalized exanthematous pustulosis]
    Jiang Lin Zhang
    Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China
    Zhongguo Dang Dai Er Ke Za Zhi 10:497-9. 2008
    ..To describe the etiology, clinical features and treatment of childhood acute generalized exanthematous pustulosis (AGEP)...
  66. ncbi [Adverse cutaneous drug reactions]
    R A Rupec
    Klinik und Poliklinik für Dermatologie und Allergologie der Ludwig Maximilians Universität München
    Dtsch Med Wochenschr 132:2685-94. 2007
  67. ncbi A four-year-old boy with fever, rash, and arthritis
    Erin F D Mathes
    Departments of Dermatology and Pediatrics, University of California, San Francisco, CA 94143 0316, USA
    Semin Cutan Med Surg 26:179-87. 2007
    ..The important features which can help distinguish these conditions include the nature of the rash, associated signs or symptoms, time course of the eruption, and characteristic laboratory and/or histologic findings...
  68. pmc Pre-engraftment syndrome in hematopoietic stem cell transplantation
    Young Ho Lee
    Department of Pediatrics and Hematopoietic Stem Cell Transplantation Center, Hanyang University Medical Center, Seoul, Korea
    J Korean Med Sci 23:98-103. 2008
    ..The close observation and further pathophysiological research are required to better understand this syndrome...
  69. doi Mercury-induced acute generalized exanthematous pustulosis misdiagnosed as a drug-related case
    Hichem Belhadjali
    Department of Dermatology, Fattouma Bourguiba Hospital, Monastir 500, Tunisia
    Contact Dermatitis 59:52-4. 2008
  70. ncbi The tumor-necrosis-factor-associated periodic syndrome, the brain, and tumor-necrosis-factor-alpha antagonists
    B Wildemann
    Division of Molecular Neuroimmunology, Department of Neurology, University of Heidelberg, Germany
    Neurology 68:1742-4. 2007
  71. ncbi Fever and rash in a child: when to worry?
    Cheryl Aber
    Miller School of Medicine, University of Miami, Department of Dermatology and Cutaneous Surgery, Cedar Medical Center, Miami, Florida 33125, USA
    Pediatr Ann 36:30-8. 2007
    ..This article is not all-inclusive but is meant to aid in the diagnosis to differentiate serious, life-threatening eruptions from more benign common rashes...
  72. ncbi 57-year-old Asian-American man with Kikuchi's disease
    Deryll U Ambrocio
    University of Hawai i, Internal Medicine Residency Program, 1356 Lusitana St, 7th Floor, Honolulu, HI 96813 2427, USA
    Hawaii Med J 65:315-7. 2006
    ..The ratio of affected women to men is 4:1 with the average age of onset less than 30 years. We report a case of KD in a 57-year-old Asian-American man whose presentation is associated with Adult Still's Disease...
  73. ncbi Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients
    Francisco Javier Peñalver
    Ann Hematol 85:400-6. 2006
    ..Rituximab induced clinical responses in multi-treated refractory ITP patients with little toxicity and should be considered as an early therapeutic option in this setting, even as an alternative to splenectomy in selected patients...
  74. ncbi Fever, eosinophilia, and a rash
    Gerlinde Obermoser
    J Am Acad Dermatol 54:913-4. 2006
  75. pmc A 2 year old with a rash
    K Martin
    Department of Neonatology, Leicester General Hospital, Leicester LE5 4PW, UK
    Postgrad Med J 82:e6. 2006
  76. ncbi [Parvovirus B19]
    A Schindler
    Medizinische Poliklinik, Universitatsspital Zurich
    Praxis (Bern 1994) 95:609-15; quiz 616. 2006
  77. ncbi Severe dapsone hypersensitivity syndrome
    O Sener
    Division of Allergy, Gulhane Military Medical Academy, Ankara, Turkey
    J Investig Allergol Clin Immunol 16:268-70. 2006
    ..We report the case of a 21-year-old female patient with dapsone hypersensitivity syndrome. The clinical presentation mimicked a viral exanthema.
  78. ncbi [Diagnostic image (281). A girl with fever, a sore throat and a rash]
    J M P J Breur
    Isala Klinieken, Amalia Kinderafdeling, Zwolle
    Ned Tijdschr Geneeskd 150:1508. 2006
    Scarlet fever was diagnosed in a girl with high fever, a sore throat and exanthema marginatum.
  79. ncbi Esophagitis and anticonvulsant hypersensitivity syndrome
    C Balatsinou
    Department of Medicine and Science of Aging, Section of Internal Medicine and Gastroenterology and Section of Infectious Diseases, G D Annunzio University and Foundation, Chieti, Italy
    Endoscopy 38:957. 2006
  80. ncbi [Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy]
    P Le Nouail
    Service de Dermatologie et Venereologie, Hopital Sud, Amiens, France
    Ann Dermatol Venereol 133:686-8. 2006
    ..Imatinib (Gleevec) is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia. We describe a case of drug reaction with eosinophilia and systemic symptoms (DRESS) after institution of treatment with imatinib...
  81. ncbi Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas
    Karoline Stur
    Division of Immunology, Allergy and Infectious Diseases DIAID, Department of Dermatology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria
    J Invest Dermatol 127:802-7. 2007
    ..As controls, healthy persons and patients with other inflammatory skin diseases such as viral exanthema were analyzed...
  82. ncbi Meningoencephalitis as a presentation of Kawasaki disease
    Entesar Husain
    Department of Pediatrics, Amiri Hospital, Adan, Kuwait
    J Child Neurol 21:1080-1. 2006
    ..The neurologic outcome of this patient was excellent, with full recovery without any neurologic deficit. The case report is followed by a review of the neurologic associations and complications of Kawasaki disease...
  83. ncbi Acute developing generalized pustular rash
    Martin J Koehler
    Department of Dermatology, Friedrich Schiller University of Jena, Jena, Germany
    Am J Clin Dermatol 9:189-92. 2008
  84. ncbi Syndromic surveillance for measleslike illnesses in a managed care setting
    James D Nordin
    HealthPartners Research Foundation, Minneapolis, Minnesota, USA
    J Infect Dis 189:S222-6. 2004
    ..Provider education regarding evaluation and reporting of measles is warranted. Databases at health care plans can be used to address public health issues and to establish syndromic surveillance for communicable diseases...
  85. ncbi Engraftment syndrome in children undergoing autologous peripheral blood progenitor cell transplantation
    L Madero
    Department of Pediatric Hematology and Oncology, Hospital Infantil Niño Jesus, Madrid, Spain
    Bone Marrow Transplant 30:355-8. 2002
    ..In summary, we have found ES to be the most important cause of morbidity and mortality in children undergoing autologous PBPCT...
  86. ncbi Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy
    M Lanzafame
    , Ospedale Civile di Legnago, Verona, Italy
    Scand J Infect Dis 33:475-6. 2001
    ..Recently the condition has been described in HIV-infected patients taking antiretroviral agents. We report the first case, to our knowledge, of DRESS syndrome complicated by meningoencephalitis associated with nevirapine therapy...
  87. ncbi Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225
    Ellen Hollywood
    Department of Gastrointestinal Medical Oncology, Memorial Sloan Kettering Hospital, 504 East 63rd St 28 N, New York, NY 10021, USA
    Semin Oncol Nurs 18:30-5. 2002
    ..To review the clinical safety experience of the monoclonal antibody IMC-C225, focusing on two clinically important adverse events: acne-like rash and allergic reactions. In addition, practical administration issues are discussed...
  88. ncbi Diagnosis and management of suspected cases of bioterrorism: a pediatric perspective
    Hanoch A Patt
    Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
    Pediatrics 109:685-92. 2002
    ..The system controlling the interaction between public and nonpublic health laboratories in suspected cases of bioterrorism is described. Finally, information regarding emergency contacts and links to educational resources is provided...
  89. ncbi [Immunoallergic interstitial nephritis vs. cholesterol atheroembolism. Differentiating characteristics]
    B Espejo
    Servicio de Nefrologia, Hospital 12 de Octubre, Avda De Córdoba, S N 28041 Madrid
    Nefrologia 23:125-30. 2003
    ..In summary, the analysis of clinical and laboratory data allows an initial differential diagnosis in patients suspected as having IIN or ATD...
  90. ncbi Visual diagnosis: a febrile child who has "red eyes" and a rash
    Muhammad Waseem
    Lincoln Hospital, Bronx, NY, USA
    Pediatr Rev 24:245-8. 2003
  91. ncbi Kawasaki disease
    Loren G Yamamoto
    University of Hawaii John A Burns School of Medicine, Emergency Department, Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, USA
    Pediatr Emerg Care 19:422-4. 2003
  92. ncbi Prolonged anticonvulsant hypersensitivity syndrome related to lamotrigine in a patient with human immunodeficiency virus
    Thomas C Beller
    Department of Medicine and Pediatrics, Harvard Medical School, Rheumatology, Immunology and Allergy Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Allergy Asthma Proc 23:415-9. 2002
    ..We report the occurrence of a prolonged hypersensitivity syndrome likely related to lamotrigine in a 32-year-old female with HIV and review the literature regarding this condition...
  93. ncbi Atypical exanthems: morphology and laboratory investigations may lead to an aetiological diagnosis in about 70% of cases
    F Drago
    DiSEM Section of Dermatology, University of Genoa, V le Benedetto XV 7, 16132 Genoa, Italy
    Br J Dermatol 147:255-60. 2002
    ..Their aetiological diagnosis is difficult but crucial for both the patient and community concerning issues such as time off school, immunizations, and risks for pregnant women and immunocompromised patients...
  94. ncbi Mevalonate kinase deficiency: Evidence for a phenotypic continuum
    A Simon
    Departments of General Internal Medicine, Section of DNA Diagnostics, Laboratory for Pediatrics and Neurology, University Medical Center St Radboud, Nijmegen, The Netherlands
    Neurology 62:994-7. 2004
    ..Mevalonate kinase deficiency should be considered in adult patients with fitting neurologic symptoms, with or without periodic fever attacks...
  95. ncbi Clinical pearls: A 2-year-old female with a rash
    Daniel E Lewis
    Department of Emergency Medicine, Brody School of Medicine at East Carolina University, Pitt County Memorial Hospital, Greenville, NC, USA
    Acad Emerg Med 11:383-7. 2004
  96. ncbi Index of suspicion
    Francesco Mulè
    Jacobi Medical Center, Bronx, NY, USA
    Pediatr Rev 25:254-9. 2004
  97. ncbi Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 30-2002. An eight-year-old girl with fever, hemoptysis, and pulmonary consolidations
    Brian P O'Sullivan
    N Engl J Med 347:1009-17. 2002
  98. ncbi Human parvovirus B19 infection in children: uncommon clinical presentations
    Judith Barash
    Division of Pediatrics, Kaplan Medical Center, Rehovot, Israel
    Isr Med Assoc J 4:763-5. 2002
    ..HPV is also suspected of playing a role in the pathogenesis of various chronic inflammatory and autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Kawasaki disease and multiple sclerosis...
  99. ncbi Acute generalized exanthematous pustulosis (AGEP), an uncommon condition in children: case report and review of the literature
    K P Meadows
    Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City 84132-0001, USA
    Pediatr Dermatol 17:399-402. 2000
    ..It is usually seen as a medication reaction. We describe a 17-month-old boy with AGEP secondary to exposure to amoxicillin. This is an uncommon condition in children...
  100. ncbi A 32-year-old man with tuberculosis, fever, and rash
    Rachel E Story
    Division of Allergy Immunology, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 14108, USA
    Ann Allergy Asthma Immunol 92:495-9. 2004
  101. ncbi Dapsone hypersensitivity syndrome masquerading as a viral exanthem: three cases and a mini-review
    A K H Tee
    Department of Medicine, Changi General Hospital, Singapore
    Ann Acad Med Singapore 33:375-8. 2004
    ..We report 3 cases of dapsone hypersensitivity syndrome due to anti-malarial chemoprophylactic treatment with maloprim, in military servicemen, presenting like a viral exanthem...

Research Grants52

  1. EIGHTEENTH INTERNATIONAL HERPES VIRUS MEETING
    Joseph Glorioso; Fiscal Year: 1993
    ....
  2. ANALYSIS OF THE HUMAN HERPESVIRUS 6 GENOMIC TERMINI
    GARY LINDQUESTER; Fiscal Year: 1992
    ..Finally, the feasibility of initiating functional analysis by generating HHV-6/CCV amplicons and intertypic recombinants will be explored...
  3. PATHOPHYSIOLOGY OF VARICELLA ZOSTER VIRUS INFECTION
    Martin Myers; Fiscal Year: 1980
    ..Both aspects of this proposal will permit examination of the specific immunologic parameters of VZV infection. ..
  4. GLYCOPROTEINS OF HUMAN HERPESVIRUS-6
    Bala Chandran; Fiscal Year: 1992
    ..The studies outlined in this proposal are significant because these studies will lead into important insight in to the biology of HHV-6...
  5. Varicella Zoster Virus:Clinical Implications of Immunity
    Saul Silverstein; Fiscal Year: 2003
    ..Finally we will identify the nuclear localization signal of ORF 29p and determine whether nuclear translocation is a prerequisite for reactivation from latency. ..
  6. DNA SCREENING ASSAY FOR HUMAN HERPES VIRUS
    Frank White; Fiscal Year: 1993
    ..In Phase II, we will refine and extend these procedures for distinguishing among the subtypes of HHV-6 that have been detected in infected clinical specimens of blood, saliva, urine, and tissue...
  7. Mechanisms and Therapeutics in Cancer Anorexia/Cachexia
    Aminah Jatoi; Fiscal Year: 2004
    ..This K23 grant application will serve as a springboard to allow her to delve into the pathophysiology of this syndrome and to develop into an independent clinical investigator. ..
  8. Creatine: Is It a Body Builder for Cancer Patients?
    Aminah Jatoi; Fiscal Year: 2004
    ..obtain longitudinal toxicity and quality of life data on this same cohort of 50 patients and will make direct comparisons between treatment arms on toxicity incidence and severity and on maximal quality of life scores ..
  9. Neuropeptide Y for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2003
    ..These two pilot studies will allow us to lay the groundwork for such larger trials. Our ultimate goal is to help cancer patients who suffer from anorexia. ..
  10. Chemotherapy and anti-EGFR Antibody C225 in Lung Cancer
    Roman Perez Soler; Fiscal Year: 2004
    ..abstract_text> ..
  11. INNOVATIVE TUMOR TARGETED THERAPIES FOR LUNG CANCER
    Roman Perez Soler; Fiscal Year: 2004
    ..Four such candidates have already been identified. It is anticipated that a total of ten young clinical investigators will be mentored during a five-year period. ..
  12. CATIONIC LIPID/P53 GENE THERAPY IN LUNG CANCER PATIENTS
    Roman Perez Soler; Fiscal Year: 2003
    ..The results of this study will provide initial but very valuable information on the potential use of this new strategy in the treatment of bronchial premalignancy, carcinoma in situ, and endobronchial lung tumors. ..
  13. Determinants of Resistance to Erlotinib in NSCLC
    Roman Perez Soler; Fiscal Year: 2010
    ..To confirm the predictive value of the algorithm in a group of patients with chemoresistant NSCLC selected for their high probability of achieving a response or stable disease with single agent erlotinib therapy. ..
  14. Long-Circulating Liposomal Camptothecins CAP and EAP
    Roman Perez Soler; Fiscal Year: 2003
    ..Ultimately, we will seek formulation(s) that display optimized drug retention and in vivo and in vitro performance. PROPOSED COMMERCIAL APPLICATION: Not Available ..
  15. Obstacles to Answering Physicians' Patient-Care Question
    John Ely; Fiscal Year: 2003
    ..Benefit: By identifying areas where knowledge resources fail to meet the needs of physicians, we will provide recommendations to help knowledge base developers better meet those needs. ..
  16. ACUTE ALPHAVIRAL ENCEPHALITIS
    Diane Griffin; Fiscal Year: 2008
    ..abstract_text> ..
  17. Infectious Diseases of the Nervous System: Pathogenesis and Worldwide Impact
    Diane Griffin; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  18. 2007 Viruses & Cells Gordon Conference
    Diane Griffin; Fiscal Year: 2007
    ..abstract_text> ..
  19. Prevention of Cytomegalovirus Infection
    Stuart Adler; Fiscal Year: 2007
    ..The results of this study will establish if prevention of CMV infections is possible. [unreadable] [unreadable]..
  20. Immune Responses During Measles Virus Infection
    Diane Griffin; Fiscal Year: 2007
    ..3. To determine the roles of different CD4 and CD8 T cell populations in production of cytokines at various times during measles and the effect of concurrent HIV infection on these roles. ..
  21. Structure & Biology of Hematopoietic E-/L-Selectin
    Robert Sackstein; Fiscal Year: 2006
    ..This information will contribute greatly to our understanding of the adhesive systems that regulate steady-state and pathologic hematopoiesis, as well as hematopoietic recovery following stem cell transplantation. ..
  22. Molecular Basis Of Renal Cell Carcinoma Response to SU11428
    Robert J Motzer; Fiscal Year: 2011
    ..These tumor and cell line-based studies lay a foundation for further molecular studies aimed at understanding the sensitivity/resistance of RCC to SU11248. ..
  23. Innate Effectors of rAls3p-N Anti-Candida Vaccine
    Brad J Spellberg; Fiscal Year: 2010
    ..PNS 398/2590 (Rev. 11/07) Page - Continuation Format Page ..
  24. Optimizing Osteotropism of Human Mesenchymal Stem Cells
    Robert Sackstein; Fiscal Year: 2010
    ....
  25. Molecular Epidemiology of Esophageal Cancer Prognosis
    Geoffrey Liu; Fiscal Year: 2008
    ..Furthermore, the proposed studies address directly a prioritized research area identified by the NCI Stomach and Esophageal Cancers Progress Review Group (Year 2002). ..
  26. Adrenergic Antagonism During Murine Candidiasis
    Brad Spellberg; Fiscal Year: 2008
    ..For these reasons, the potential for adrenergic antagonism to act as an effective immunotherapy is highly meritorious of investigation in this training application. ..
  27. Gene Expression in Acute and Chronic Neurologic Disease
    Donald Gilden; Fiscal Year: 2008
    ..This concerted effort is focused on prospective studies to delineate the cause, pathogenesis and eventual prevention of viral and demyelinating diseases of the human nervous system. ..
  28. Antiretroviral Therapy and the Hepatitis C Virus
    Kenneth E Sherman; Fiscal Year: 2010
    ....
  29. Characterization of A Novel 65kDa E-selectin Ligand on G-CSF Mobilized Leukocytes
    Robert Sackstein; Fiscal Year: 2008
    ..It is anticipated that the results obtained will lead to new approaches for preventing or alleviating G-CSF-induced vascular and inflammatory complications [unreadable] [unreadable] [unreadable]..
  30. AIDS-ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM
    David Aboulafia; Fiscal Year: 2005
    ..5. Assist the AMC and the NCI clinical trials cooperative groups and the NIAID ACTUs in the development and implementation of phase III studies if initial efforts of the AMC consortium are successful. ..
  31. MEASLES VACCINES--IMMUNE RESPONSES AND ATYPICAL MEASLES
    Diane Griffin; Fiscal Year: 2001
    ....
  32. ADHESION MOLECULES MEDIATING SKIN TROPISM IN ACUTE GVHD
    Robert Sackstein; Fiscal Year: 2003
    ....
  33. HCV Genomic Variability in HIV Infected Hemophiliacs
    Kenneth Sherman; Fiscal Year: 2004
    ..Treatment nonresponders will be followed in a prospective cohort study for up to 3 additional years so that the evolution of the virus, and its associated immune response in this group can be evaluated. ..
  34. MIDCAREER INVESTIGATOR AWARD IN NEURO-AIDS RESEARCH
    David Simpson; Fiscal Year: 2005
    ..The Neuro-Adherence Program will assess the affect of neurological disease on patients' adherence to medical regimens, and the impact of education and support groups on adherence. ..
  35. Novel regulatory role of cryopyrin in inflammation
    Harold Hoffman; Fiscal Year: 2005
    ..abstract_text> ..
  36. ADJUVANT HORMONAL THERAPY IN VIETNAMESE BREAST CANCER
    Richard Love; Fiscal Year: 2005
    ..The investigators have a trial with a rich database and systems to develop further useful data on breast cancer relevant to all women. ..
  37. 2nd International Cervical Cancer Conference
    Michele Follen; Fiscal Year: 2002
    ..Each session chair and speaker has been chosen based on his/her publications, funding and national reputation. ..
  38. LIVE, ATTENUATED, RECOMBINANT VACCINE - WEST NILE VIRUS
    Thomas Monath; Fiscal Year: 2002
    ..abstract_text> ..
  39. GENETIC AND MOLECULAR BASIS OF FAMILIAL COLD URTICARIA
    Harold Hoffman; Fiscal Year: 2002
    ..The achievement of these goals will result in identification of the gene responsible for familial cold urticaria which will ultimately lead to an understanding of the mechanism of the inflammatory response to a physical stimulus. ..
  40. Norepinephrine and Impulsivity
    Alan Swann; Fiscal Year: 2009
    ..The results of these experiments may suggest means for monitoring risk for impulsive behavior and for a rational treatment schema for impulsivity. ..
  41. CLINICAL TRAILS IN PEDIATRIC RHEUMATOLOGY
    Daniel Lovell; Fiscal Year: 2004
    ..2. Determine the long-term efficacy and safety of these treatment regimens in sJRA. ..
  42. A pharmacogenetic and pharmacodynamic study of erlotinib
    CHARLES RUDIN; Fiscal Year: 2004
    ..Defining the basis of this toxicity could also promote the development of EGFR-directed agents that may avoid such toxicity or that may be effective in a broader spectrum of cancer patients. ..
  43. Phase I/II Study of MS-275 and 5-Azacytidine in Patients with Advanced Non-Small
    CHARLES RUDIN; Fiscal Year: 2008
    ..If successful, this approach could alter the poor prognosis of individuals with this disease. [unreadable] [unreadable] [unreadable]..
  44. Dectection of occult mediastinal lymph node mestastases
    Michael Wallace; Fiscal Year: 2007
    ..In the R33 component of the grant application these criteria will be prospectively evaluated and correlated with clinical outcome in a second, larger cohort of patients. ..
  45. Mosquito Immunity to Alphaviruses
    Brian Foy; Fiscal Year: 2006
    ..3) Characterize the mechanisms that Culex tritaeniorhynchus mosquitoes use to clear Sindbis virus-infected midgut cells. [unreadable] [unreadable]..
  46. Randomized Trial of EUS Neurolysis in Pancreas Cancer
    Michael Wallace; Fiscal Year: 2006
    ..The primary outcome will be a reduction in pain at 1 month. Secondary outcomes will include the durability of pain control, quality of life, narcotic use and narcotic side effects. [unreadable] [unreadable]..
  47. BEHAVIORAL INTERVENTION FOR CONGENITAL CMV DISEASE
    Stuart Adler; Fiscal Year: 2001
    ..The results of this trial will determine the effectiveness of behavioral intervention and the motivation necessary to adhere to recommendations and prevent child-to-mother transmission of CMV. ..
  48. EPIDEMIOLOGY OF CMV
    Stuart Adler; Fiscal Year: 2007
    ..The results of this study will establish if immunization of mothers against CMV infection is possible. ..
  49. CLINICAL TRIALS AND MENTORING IN ONCOLOGY RESEARCH
    Robert Motzer; Fiscal Year: 2003
    ..One recently joined staff at MSKCC in the Genito-urinary Section. Mentoring of clinical trials is extended beyond fellowship to junior faculty members. ..
  50. 10th International CMV Workshop
    Stuart Adler; Fiscal Year: 2005
    ..The purpose is to keep everybody up to date and current about what's going on in all areas and stimulate new research projects and collaborations. We anticipate between 300 and 500 attendees. ..